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Abstract
Background:  Diabetes  mellitus  2  has  become  a  global  problem.  It  is  estimated  that  15--25%  of
patients could  develop  a  chronic  ulcer  in  their  life,  and  nearly  33%  of  direct  care  costs  of  the
diabetes mellitus  2  is  spent  on  treating  these  ulcers.  Mesenchymal  stem  cells  have  emerged  as
a promising  cell  source  for  the  treatment  of  these  ulcers.
Clinical  case:  The  case  is  presented  of  a  67  year-old  male  with  a  history  of  diabetes  mellitus,
acute myocardial  infarction,  and  chronic  ulcer  involving  right  foot  and  part  of  his  leg.  He  was
treated with  mesenchymal  stem  cell  management,  resulting  in  skin  graft  integration  and  full
coverage  of  the  lesion.
Conclusion:  The  implementation  of  mesenchymal  stem  cell  techniques  for  treatment  of  chronic
ulcer is  feasible.  The  impact  on  the  population  would  lead  to  a  signiﬁcant  improvement  in  their
quality of  life  and  reduce  healthcare  spending.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This  is
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PALABRAS  CLAVE
Células  troncales
mesenquimales;
Úlcera  crónica;
Diabetes  mellitus  tipo
2
Células  troncales  mesenquimales  autólogas  e  injerto  cutáneo  autólogo  para
tratamiento  de  una  úlcera  crónica  secundaria  a  diabetes  mellitus  tipo  2
Resumen
Antecedentes:  La  diabetes  mellitus  tipo  2  se  ha  convertido  en  un  problema  a  nivel  mundial.
Se estima  que  del  15  al  25%  de  los  pacientes  desarrollarán  una  úlcera  crónica  a  lo  largo  de  su
vida, y  cerca  del  33%  de  los  costos  directos  de  atención  a  diabetes  mellitus  tipo  2  se  gasta  en
la atención  de  estas  úlceras.  Las  células  troncales  mesenquimales  han  surgido  como  una  fuente
celular prometedora  para  el  tratamiento  de  este  tipo  de  úlceras.
Caso clínico: Masculino  de  67  an˜os  con  antecedentes  de  diabetes  mellitus  tipo  2,  infarto  agudo
de miocardio  y  úlcera  crónica  en  miembro  inferior  derecho  que  involucra  la  cara  interna  del
pie y  parte  de  la  pierna  derecha;  se  le  trató  con  células  troncales  mesenquimales,  resultando
una adecuada  integración  del  injerto  de  piel  y  la  cobertura  total  de  la  lesión.
Conclusión:  La  implementación  de  células  troncales  mesenquimales  para  el  tratamiento  de  la
úlcera crónica  es  factible.  El  impacto  en  la  población  sería  importante,  al  mejorar  la  calidad
de vida  de  los  pacientes  y  disminuir  los  costos  de  atención.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este  es
un artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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was  indicated.  Subsequent  to  describing  the  procedures,
the  risks  and  probabilities  of  both  improvements  from  bothBackground
Diabetes  mellitus  type  2  has  become  a  global  problem.  It
is  estimated  that  in  the  year  2030  a  70%  concentration  of
patients  with  this  disease  will  live  in  developing  countries,
and  Mexico  will  Rank  sixth  or  seventh  in  the  international
league.1 If  we  take  into  consideration  current  trends  and
behaviour  patterns  of  diabetes  mellitus  type  2  patients,
the  long-term  complications  of  this  disease,  which  include
nephropathy,  retinopathy,  peripheral  vascular  disease  and
neuropathy  pose  a  real  challenge  to  the  medical  profession
due  to  their  complexity.2,3 It  is  estimated  that  15--25%  of  dia-
betes  mellitus  type  2  patients  will  develop  a  chronic  ulcer
during  their  lifetime,  and  this  population  is  also  10--20  times
more  likely  to  undergo  non-traumatic  amputation  of  a  limb,
compared  with  the  population  which  does  not  present  with
this  pathology.4--9 The  social  impact  of  this  type  of  lesion
must  be  considered,  since  the  average  duration  of  an  ulcer
is  between  12  and  13  months;  nearly  70%  of  patients  who
have  had  an  ulcer  will  present  with  at  least  one  other  ulcer
during  their  lifetime,  with  a  consequential  estimated  loss  of
2  million  working  days  from  inability  to  work.10 In  2010  alone
it  was  estimated  that  Mexico  spent  778,427,475  US  dollars  on
DM2  medical  attention11--17 (US$343,226,541  on  direct  costs
and  US$435,200,934  on  indirect  costs),18 and  nearly  33%  of
direct  care  costs  of  diabetes  mellitus  type  211--17 was  spent
on  treating  chronic  ulcers.19
One  of  the  problems  we  encounter  on  treating  this  type
of  lesion  is  the  low  probability  of  success,  since  under  the
best  conditions  only  50%  of  all  cases  remit,  and  for  the
other  50%  of  patients  the  ulcers  are  one  of  the  main  rea-
sons  for  amputation,  with  an  estimated  one-year  survival
for  70%  of  patients  and  ﬁve  years  for  20%.20 Regarding  the
organic  characteristics  leading  to  the  ulcers,  including  insuf-
ﬁcient  tissue  perfusion  from  microvasculature  damage,2,3
treatment  based  on  cells  or  their  products  (cell  therapy)  has
recently  been  proposed  to  improve  microvasculature  repair
p
a
sechanisms  and  stimulate  re-epithelisation.21 These  new
lternatives  propose  a  treatment  based  on  mesenchymal
tem  cells,  on  the  premise  that  these  cells  produce  mod-
lators  which  affect  both  the  inﬂammatory  response  and
rowth  factors  for  tissue  regeneration.11,22
Mesenchymal  stem  cells  are  formed  during  embryonic  life
n  the  mesoderm,  giving  rise  to  connective  tissue,  bone,
uscle  and  cartilage.  Once  the  embryo  has  formed  stem
ells  reserves  remain  almost  throughout  the  whole  body  and
hey  may  be  identiﬁed,  as  may  their  function,  through  the
se  of  speciﬁc  cell  markers.  These  cells  have  been  identiﬁed
n  bone  marrow,  the  umbilical  cord,  fatty  tissue  and  pla-
enta  tissue.  Clinically  they  may  be  used  in  ulcers  of  diverse
etiology,  with  the  exception  of  neoplastic  ulcers.
The  aim  of  this  paper  is  to  share  our  recorded  experience
ith  autologous  mesenchymal  stem  cells  as  treatment  for  a
atient  with  a  chronic  ulcer  secondary  to  diabetes  mellitus
ype  2.11--17
linical case
 67  year  old  man  with  a  15  year  history  of  diabetes  mellitus
ype  2  was  assessed  by  the  Orthopaedic  Unit  in  the  Hospital
eneral  de  Puebla  for  a  chronic  ulcer  (of  one-year  duration)
n  the  right  pelvic  limb,  which  had  spread  from  the  inner  side
f  the  foot  on  the  sole,  involving  the  ﬁrst  and  second  toes,
p  the  inner  side  of  the  leg  to  its  middle  third.  Culture  test-
ng  of  the  lesion  revealed  Staphylococcus  sp.  and  Escherichia
oli.  Given  the  conditions  of  the  ulcer  and  the  fact  that  this
as  a  multi-treated  patient,  therapeutic  amputation  or  the
se  of  mesenchymal  stem  cells  with  autologous  skin  graftrocedures,  the  patient  chose  mesenchymal  stem  cells  and
utologous  skin  graft  and  gave  his  written  consent  to  the
ame.
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able  to  put  weight  on  the  limb,  and  after  a  year  he  continued
to  be  complication  free.  The  patient’s  evolution  is  shown  in
Figs.  1--4.
Figure  1  Wound  area  involved.34  
The  ﬁrst  step  consisted  in  keeping  the  patient  hos-
italised  whilst  the  infection  was  controlled  using  third
eneration  cephalosporins;  an  initial  debridement  was  per-
ormed,  in  addition  to  the  amputation  of  the  ﬁrst  and  second
oes.  Four  further  surgical  interventions  were  performed
with  15  day  spacing  between  each  one).  During  the  ﬁrst
urgical  intervention  scariﬁcation  of  the  injury  was  made
nd  puncture  of  the  spinae  for  the  obtainment  of  60  ml  of
one  marrow;  citrate  phosphate  dextrose  was  used  to  pre-
ent  coagulation  of  the  specimen  and  for  cell  maintenance;
he  specimen  was  then  submitted  for  processing  in  the  Lab-
ratorio  de  Medicina  Regenerativa  in  coordination  with  the
aboratorio  de  Morfología  de  la  Escuela  Superior  de  Medicina
el  Instituto  Politécnico  Nacional  to  obtain  and  cultivate  the
esenchymal  stem  cells  for  30  days.
esenchymal  stem  cell  isolation
he  mesenchymal  stem  cells  were  obtained  by  bone  marrow
spiration  of  the  ileum  using  a  60  ml  syringe  with  citrate
hosphate  dextrose  as  the  anti-coagulant.  The  aspired
aterial  was  diluted  in  a  sterile  medium  of  1:2  parts  with  a
olution  of  sterile  PBS1× and  centrifuged  at  a  density  gra-
ient  of  NycoPrepTM  1.077  g/ml,  for  30  min  at  1500  rpm.
ononuclear  cells  were  separated  from  the  interface  and
ere  washed  on  2  occasions  with  PBS1× solution,  cen-
rifuged  for  10  min  at  2000  rpm  and  seeded  into  25  cm
CORNING)  Petri  dishes  with  5  ml  of  poietics  human  mes-
nchymal  stem  cells  medium,  at  37 ◦C  and  5%  of  CO2;  this
as  supplemented  with  1×  antibiotic--antimicotic.  After  3
ays  it  was  washed  with  the  1×  citrate  phosphate  dextrose
olution  to  remove  non  adherent  cells  and  a  fresh  medium
as  added.
Once  a  cellular  conﬂuence  of  70--80%  had  been  obtained,
he  adherent  cells  were  detached  using  an  EDTA  trypsin  solu-
ion  (0.025%,  GIBCO)  and  incubated  for  10  min  at  37 ◦C.  The
ells  were  washed  with  PBS  and  seeded  into  a  2  ×  103  cell/ml
olution  in  100  mm  ×  20  mm  (CORNING)  Petri  dishes  now
ith  10  ml  of  DMEM/F-12  and  an  addition  of  10%  SFB  and
ntibiotics.  These  cells  were  reseeded  up  to  three  times
or  assessment  of  membrane  markers  by  ﬂow  cytometry;
heir  plasticity/cellular  differentiation  to  osteoblasts  and
dipocytes  was  also  assessed.
Characterisation  of  the  mesenchymal  stem  cells  was
erformed  by  assessing  the  surface  markers  (anti-CD73,
nti-CD90  anti-CD105,  anti-CD14,  anti-HLA-DR,  anti-CD13
nd  anti-CD45)  by  ﬂow  cytometry.  The  results  obtained
howed  that  new  cells  expressed  high  levels  of  CD73,  CD90,
D105  and  CD13.  However,  they  did  not  express  haemato-
oietic  markers  such  as  CD45,  CD14  and  HLA-DR.
Cellular  plasticity  was  assessed  whilst  cultivating  the
ells  in  the  presence  of  speciﬁc  differentiating  media
ncluding:  StemPro  Adipocyte  Differentiation  Basal  Medium
nd  StemPro  Ostecyte/Chondrocyte  Differentiation  Basal
edium  (GIBCO)  for  15  days.  The  results  obtained  indicated
hat  our  cells  are  able  to  differentiate  themselves  from  both
dipocytes  and  osteoblasts.During  the  second  and  third  surgical  intervention  surgical
leaning  of  the  site  was  carried  out,  and  during  the  fourth
ntervention  the  autologous  mesenchymal  stem  cells  were
laced  on  a  clean  site  suspended  in  platelet-rich  plasma,
F
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ith  a  distribution  of  1  million  cells  per  cm2,  after  which  an
utologous  cutaneous  graft  of  15  cm  ×  10  cm  (mesh)  taken
rom  the  ipsilateral  thigh  was  inserted.  The  graft  was  cov-
red  with  vaseline-covered  gauzes  and  500  mg  ciproﬂoxacin
as  administered  for  2  weeks.  The  patient  was  assessed  on
 weekly  basis,  with  the  total  integration  of  the  graft  being
ocumented  2  weeks  later;  6  months  later  the  patient  wasigure  2  Application  of  autologous  graft  and  autologous  mes-
nchymal  cells.
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Figure  3  Patient  assessments  after  7  days. F
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It  is  of  note  that  the  preparation  of  autologous  mes-
enchymal  stem  cells  from  bone  marrow  was  carried  out
in  the  Laboratorio  de  Medicina  Regenerativa  y  Cáncer  in
coordination  with  the  Laboratorio  de  Morfología,  both  from
the  Escuela  Superior  de  Medicina  del  Instituto  Politéc-
nico  Nacional,  complying  with  criteria  established  by  the
Sociedad  Internacional  de  Terapia  Celular  (ISCT),  which
includes  veriﬁcation  of  identity  by  ﬂow  cytometry  express-
ing  main  (positive)  markers  CD105,  CD73,  CD90  and  not
expressing  mainly  (negative)  CD45,  CD34,  HLA-DR12 ones,
in  addition  to  trypan  blue  veriﬁcation  of  cellular  viability  at
95%  and  conﬁrming  the  presence  of  a  bacteria-free  solution
through  a  culture,  and  with  the  veriﬁcation  of  the  cellu-
lar  morphology  under  a  simple  microscope.  Moreover,  as  a
control  measure,  an  aliquot  of  the  autologous  mesenchy-
mal  stem  cells  was  taken  from  the  wound,  which  were  later
recovered,  sown  and  multiplied  again  in  the  laboratorio  de
m
R
d
oigure  5  Light  microscope  of  mesenchymal  cells  obtained
rom the  patient.
edicina  Regenerativa  y  Cáncer  of  the  Instituto  Politécnico
acional,  with  conﬁrmation  of  their  biological  characteris-
ics  (Fig.  5).
iscussion
iabetes  mellitus  type  211--17 and  its  complications  is  a
ajor  ﬁnancial  drain  on  global  health  systems,  and  Mex-
co  is  no  exception.  It  will  rank  high  among  countries  in
030  and  economic  pressure  for  care  resulting  from  this
isease  is  increasing  disproportionately.8,19 Chronic  ulcers
re  one  of  the  main  complications,  and  are  one  of  the
ain  causes  of  amputation  due  to  complex  management
nd  treatment.6--10,18--20 During  the  last  3  decades  the  rise
n  cellular  therapies  has  enabled  other  therapeutic  options
o  become  available,  thus  changing  this  scenario  to  such
n  extent  that  they  are  now  considered  to  be  better  cost-
ffective  options,13,14 and  are  now  included  in  international
lcer  management  guidelines  such  as  those  from  Sociedad
e  Atención  de  Heridas,15--17 and  those  of  several  hospital
rotocols,  such  as  the  Mount  Sinai  Hospital  in  New  York.
Mesenchymal  stem  cells  have  been  successfully  used  with
his  type  of  lesion  due  to  their  ability  to  regulate  inﬂamma-
ory  processes  and  regenerate  tissue  through  factors  such
s  interleukin-10  and  interleukin-4,  in  addition  stimulating
ew  vessel  growth  by  vascular  growth  factor,  growth  factor
erived  from  platelets,  recruiting  of  keratinocytes,  markings
or  the  migration  of  native  stem  cells  and  ﬁnally  remodelling
f  the  wound  through  regulation  of  keratinocytes  and  the
resence  of  growth  factor    and  metaloproteinases,23 key
lements  for  tissue  regeneration.
The  transdisciplinary  approach  enabled  this  patient  to
reserve  his  limb.  Correct  disease  management  by  the
edical  and  surgical  team  from  the  orthopaedic  Unit  of
he  Hospital  General  de  Puebla  to  control  infection  and
lean  the  site,  together  with  the  obtainment  of  autologous
esenchymal  stem  cells  from  the  Laboratorio  de  Medicina
egenerativa  y  Cáncer,  in  coordination  with  the  Laboratorio
e  Morfología,  both  from  the  Escuela  Superior  de  Medicina
f  the  Instituto  Politécnico  Nacional  with  the  highest  quality
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236  
haracteristics,  enabled  acceptance  of  the  graft  by  the
atient  and  the  ulcer  wound  bed  to  be  covered.  Under
ther  conditions  the  limb  would  have  been  amputated.  The
xistence  of  strong  cooperation  between  the  transdisci-
linary  team  was  key  in  this  regard,  since  if  one  person
oes  not  appropriately  carry  out  his  or  her  role  the  success
f  treatment  may  be  compromised.
This  type  of  transdisciplinary  approach  has  enabled
atients  to  be  treated  in  a  non  conventional  therapeutic
anner,  offering  them  an  alternative  option  to  amputation.
onclusion
he  use  of  a  cell-based  therapy  --  and  in  this  particular  case
esenchymal  stem  cells  --  is  a  global  reality  with  beneﬁts
or  both  patients  and  health  care  systems.  The  use  of  these
echniques  is  feasible  in  our  area  and  its  impact  on  the  pop-
lation  affected  by  this  type  of  disease  would  be  high,  with
ubsequent  improvement  in  quality  of  life  and  lower  health
are  expenditure.
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